PSYC 210 Lecture Notes - Lecture 12: Striatum, Dsm-5, Hypothalamus
30 Apr 2018
School
Department
Course
Professor
!"#$%&'()*($+,-.$'/##-0+#"'1/'
!"#$%&%'()#*#+,*&-.
/$0"(12(3#+."4(5--1$6&%'(*1(,10$(71189(*$#0:#.(-#0."6(7,(;0:#%.(#$"(:1$"(+&8"+,(*1(
-#0."(</=>(*;#%(#$"(%#*0$#+(6&.#.*"$.?
ANSWER4(TRUE
>"-$"#."6('$",@:#**"$(A1+0:"(12(B;&-;(7$#&%(#$"#(;#.(7""%(#..1-&#*"6(B&*;(71*;(
</=>(#%6(:#C1$(6"D$"..&1%E
=*$&#*0:
5?
Hippocampus
F%"(12(*;"(:1$"(#--0$#*"(7$#&%(&:#'"(#%#+,.".(21$(</=>(#%6(G>>
○
B.
5:,'6#+#
)?
H%.0+#
>?
I,D1*;#+#:0.
J?
What are some protective factors the book discussed that may help a person
cope with severe traumas in a more adaptive way (select all that apply)?
High2intelligence
A.
!1B(":D#*;,
K?
Strong2social2support
C.
I&';(+"A"+.(12(:1*&A#*&1%
>?
>&"*(#%6(JL"$-&."
J?
>=G@M(-$&*"$&#(21$(</=>
Exposure.to.threat
Direct.experience
○
Witnessing.an.event
○
Experience.of.someone.close
○
Repeated.exposure
○
N
One.or.more.of
Intrusive.memories
○
Recurrent.nightmares
○
Dissociations.(flashbacks)
○
Cue-induced.distress.or.panic
○
Cue-induced.physiological.reactions
○
N
Persistent.avoidance.
Avoidance.of.memories,.reminders
○
Avoidance.of.external.reminders
○
Cognition.of.mood.changes
○
Inability.to.remember.the.event
○
Negative.beliefs,.guilt,.anhedonia
○
N
Changes.in.arousal
Increased.irritability
○
Elevated.startle
○
Hypervigilance
○
Sleep.disturbance
○
Problems.with.concentration
○
N
>".-$&D*&1%(#%6(6&#'%1.&.
O".D1%."(*1("LD1.0$"(12(*;"(6&.*$"..&%'("A"%*(-$"#*".(."%.1$,9(D;,.&1+1'&-#+9(1$(
-1'%&*&A"($"#-*&1%.
N
<"$.&.*"%*(#A1&6#%-"(12($":&%6"$.(12(*;"(6&.*$"..&%'("A"%*(#%6(%"'#*&A"(10*+118(
60"(*1("A"%*(*;#*(1--0$$"6
)1::1%(B&*;(#%;"61%&#(#%6(%"'#*&A"(7"+&"2.(*1(+"#6(*1(-1:1$7&6(
6"D$"..&1%
○
N
/$"#*:"%*
<;#$:#-1+1'&-#+4
K"%P16&#P"D&%".((Q'116(.;1$*(*"$:9(D11$(+1%'(*"$:9(+&8"+,(60"(*1(
B1$."%&%'("L*&%-*&1%
31$(#-0*"(#%L&"*,
§
)#%(61(+1%'(*"$:(;#$:
§
○
="$1*1%"$'&-(#'"%*.(Q&%-$"#."(."$1*1%&%(20%-*&1%&%'9(&%-$"#."6(
*1+"$#%-"(*1(#A"$.&1%9(6"-$"#."6(.*$"..R2"#$($".D1%."9(*$1D;&-(#-*&1%
○
S1$#6$"%"$'&-(#'"%*.(T-1$$"-*(6,.$"'0+#*"6(SJ(.,.*":9(B&*;(.&:&+#$(
-;#%'".(#.(#71A"
○
N
JLD1.0$"(*;"$#D,4(D$&%-&D+".(12("LD1.0$"(*;"$#D,(#$"U
522"-*&A"($"'0+#*&1% T$"+#L#*&1%( *$#&%&%'9(-1D&%'(B&*;(.*$"..(*"-;%&V0".
○
W;&+"(7"&%'(D$1'$"..&A"+,("LD1."6(*1(*;"(2"#$"6(.*&:0+0.(TD;17&-(
.*&:0+0.9(</=>(:":1$&".9(#'1$#D;17&-(.&*0#*&1%.
○
N
)1'%&*&A"@7";#A&1$#+(*$"#*:"%*.
JLD1.0$"
○
5%L&"*,(:#%#'":"%*(*"-;%&V0".
○
N
J,"(:1A":"%*(6"."%.&*&P#*&1%(#%6($"D$1-"..&%'(XJG>OY(
5%1*;"$(21$:(12("LD1.0$"
○
JLD1.&%'(,10$."+2(*1(#(:":1$,(#'#&%
○
N
Z$10D(*;"$#D,N
[.&%'(7&1+1'&-#+(#'"%*.(*1("%;#%-"(*;"("22&-#-,(12(7&1+1'&-#+(&%*"$A"%*&1%
D-Cycloserine "%;#%-".(*;"(."%.&*&A&*,(12(SG>5($"-"D*1$.9(#(8",(:"-;#%&.:(&%(
+1%'@*"$:(D1*"%*&#*&1%(X+"#$%&%'Y
I1D"20++,(B10+6(%""6(+"..("LD1.0$"(*;"$#D,(7"-#0."(&*\.(A"$,(D#&%20+(21$(
*;"(D#*&"%*
/#$'"*(&%*"$A"%*&1%(*1(*#8"($&';*(7"21$"(*;"$#D,(&%*"$A"%*&1%(#%6(
1%+,(%""6(&*(60$&%'("LD1.0$"
§
Strong2interaction2between2drugs2and2therapy2instead2of2focusing2
on2each2as2individual2entities
§
○
[."6(*1(;"+D(*07"$-0+1.&.(70*(#+.1(;#.(7""%(210%6(*1(;#A"(D.,-;1#-*&A"(
#22"-*.(7,(7&%6&%'(*1(*;"(SG>5($"-"D*1$
H%-$"#.".(*;"(."%.&*&A&*,(12(*;"($"-"D*1$(*1(&%-1:&%'('+0*#:#*"9(
:1$"(+&8"+,(*1(6"*"-*(#($".D1%."
§
○
I"+D.(2#-&+&*#*"(+"#$%&%'9(".D"-&#++,(#..1-&#*&A"(-1%6&*&1%&%'
○
!1%'(*"$:(D1*"%*&#*&1%(@@](;1B(*B1(%"0$1%.(.,%-(0D(*;"&$(2&$&%'($#*".
○
N
G16"+.(12($".&+&"%-"("LD"$&:"%*
!118.(#*($1+"(12(D"$-"&A"6(-1%*$1++#7&+&*,(&%(:"6&#*&%'($".D1%.".(*1(.*$"..1$.N
/;$""(-;#:7"$(D#$#6&':(12(*B1($#*".(B;1."(*#&+.(;#A"(#(+11D(#$10%6(*;":(*;#*(
'"*(#%("+"-*$&-#+( .;1-8(X.#:"(.;1-8("A"$,(*&:"Y
N
)1%6&*&1%.4
J.-#D#7+"(-1%6&*&1%(X'"*.(.;1-8Y
I#.(B;""+(&%(2$1%*(*;#*(B;"%(;"(.D&%.9(;"(-#%(*0$%(122(*;"(.;1-8(21$(
71*;($#*.
§
I#.(#%("LD"$&"%-"( 12(-1%*$1+(
§
○
H%".-#D#7+"(X'"*.(.;1-8Y
S1*;&%'(;#DD"%.(B;"%(;"(.D&%.(*;"(B;""+
§
=;1-8(&.(1%(0%*&+($#*(&%(*;"(".-#D#7+"(-1%6&*&1%(*0$%.(&*(122
§
○
)1%*$1+(X%1(.;1-8Y
○
N
O".0+*.4
H%".-#D#7+"($#*(6"A"+1D.(+"#$%"6(;"+D+"..%"..
JA"%(B;"%('&A"%(#%(1DD1$*0%&*,(*1(*0$%(122(*;"(.;1-89(&*(61".%\*(#%6(
C0.*('&A".(0D
§
○
H2(;"(.*&:0+#*".(*;"(:<3)(&%(*;"(&%".-#D#7+"(-1%6&*&1%9(;"(-10+6(D$"A"%*(
*;"(6"A"+1D:"%*(12(*;"(;"+D+"..($".D1%."
○
H2(,10(6"#-*&A#*"(:<3)(21$(".-#D#7+"(-1%6&*&1%9(&*(&%60-".(;"+D+"..%"..
○
<$1A&6"("LD1.0$"(*1(*;"(".-#D#7+"(-1%6&*&1%(7"21$"(D0**&%'(&*(&%(*;"(
&%".-#D#7+"(-1%6&*&1%9(&*(-#%(D$"A"%*(#'#&%.*(*;"(6"A"+1D:"%*(12(
;"+D+"..%"..
○
N
G"#%&%'(X&%($#*.Y4
H2(.1:"1%"(;#.(#(;&.*1$,(12("LD"$&"%-".(B;"$"(*;",(D"$-"&A"(*;",(;#A"(
.1:"(-1%*$1+(1A"$(*;"(.*$"..1$(&%(*;"&$(+&A".9(*;",\$"(:1$"(+&8"+,(*1(
$".D1%6(#6#D*&A"+,
JA"%(&2(.*$"..1$(&.(10*(12(*;"&$(-1%*$1+
§
<$"A"%*&%'(+"#$%"6(;"+D+"..%"..($".D1%."(
§
K,(-1%*$1++&%'(D$&1$("LD1.0$"(1$(6&$"-*(:#%&D0+#*&1%(12(:"6&#+(
D$"2$1%*#+(-1$*"L
§
○
N
234+/$5-6667-!&.0
/;0$.6#,9( 3"7$0#$,( ^^9(^_`a
`^4^b(<G
Document Summary
True of false: according to your book, traumas caused by humans are more likely to cause ptsd than are natural disasters. Decreased grey-matter volume of which brain area has been associated with both. One of the more accurate brain image analyses for ptsd and mdd. Response to exposure of the distressing event creates sensory, physiological, or cognitive reactions. Persistent avoidance of reminders of the distressing event and negative outlook due to event that occurred. Common with anhedonia and negative beliefs to lead to comorbid depression. Benzodiazepines good short term, poor long term, likely due to worsening extinction. Serotonergic agents increase serotonin functioning, increased tolerance to aversion, decreased stress/fear response, trophic action. Noradrenergic agents correct dysregulated ne system, with similar changes as above. Affective regulation relaxation training, coping with stress techniques. While being progressively exposed to the feared stimulus phobic stimulus, ptsd memories, agoraphobic situations. Using biological agents to enhance the efficacy of biological intervention.
